linjc16/ctgov huggingface dataset:
Trajectories of Regenerating Family Resilience in Adolescents With Cancer

Study Overview
=================
Brief Summary
-----------------
Family resilience is an important strength to help family to manage life challenge successfully, and to reorganize family function. However, few studies have showed the trajectory of family resilience in adolescents with cancer over time. The purposes of this study are to know the trend of family resilience in adolescents with cancer from previous 3 months to the first year of newly diagnosed, and to examine the relationships among family members' stress, family satisfaction, and family resilience in adolescents with cancer.

Detailed Description
-----------------
The inclusion criteria of adolescents with cancer are: 1) 12-20 years of age, 2) newly diagnosed with cancer about 3 months, 3) willing and able to complete own report questionnaires. The study is designed as repeated measurement. Considering attrition rate may be more than 60%. Therefore, of necessity, the proposed sample size was set at 60 families. Data will be collected by a structured questionnaire (a demographic questionnaire and 4 scales). The study consists of four times of data collection time point as follows: approximately 3 month (t1), 6 months (t2), 9 months (t3), and 12 months (t4) after the diagnosis of cancer in adolescents. Each participant may take 20-30 minutes to finish the structured questionnaire.

Official Title
-----------------
Trajectories of Regenerating Family Resilience in Adolescents With Cancer

Conditions
-----------------
Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The inclusion criteria of adolescents with cancer are: 1) 12-20 years of age, 2) newly diagnosed with cancer about 3 months, 3) willing and able to complete own report questionnaires. Exclusion Criteria: terminal stage

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| cancer adolescent<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cancer adolescent, resilience
Biological Mesh Repair of Complex Hernias in High Risk Patients

Study Overview
=================
Brief Summary
-----------------
Complex ventral hernia repair is a significant surgical challenge with high frequencies of both wound complications and recurrence. The Ventral Hernia Working Group (VHWG) described in 2010 recommendations regarding grading and technique of repair, which we have followed since November 2011.The purpose of the this study was to evaluate our results after biologic mesh repair of complex hernias.

Detailed Description
-----------------
Obervational study Primare outcome: Surgical site occurence Secondary outcome: Hernia recurrence Biolocal mesh: Ventral hernia repair in a population with severe co-morbidity and contaminated hernia.

Official Title
-----------------
Biological Mesh Repair of Complex Ventral Hernias in High Risk Patients

Conditions
-----------------
Hernia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Abdominal wall reconstruction with biological mesh - Exclusion Criteria: Pregancy, -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| surgical site occurence | Wound infections, redness, seromas, dehiesience at the hernia implant site | 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| hernia recurrence | Hernia recurrence at the hernia implant site | 20 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
biological mesh, contaminated hernia, abdominal wall reconstruction
Analysis of Biomarkers for Acute Graft-versus-Host Disease (GVHD)

Study Overview
=================
Brief Summary
-----------------
Samples of blood and urine will be analyzed for biomarkers to check their predictivity of Graft-versus-Host Disease (GVHD) outcomes.

Detailed Description
-----------------
To determine if serum biomarkers of inflammation correlate with onset and severity of acute GVHD, particularly GVHD of the gut.

Official Title
-----------------
Analysis of Biomarkers for Acute Graft-versus-Host Disease (GVHD).

Conditions
-----------------
Blood Stem Cell Transplant Failure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years old or older patients Undergoing allogeneic stem cell transplant Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Post allogeneic SCT patients<br>Patients who have undergone an allogeneic stem cell transplant. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnosis of severe acute GVHD |  | 2 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Allogeneic stem cell transplant, Graft versus Host Disease, GVHD
Infective Endocarditis After TAVR

Study Overview
=================
Brief Summary
-----------------
This study aims at studying the frequency of infective endocarditis after transcatheter aortic valve replacement/implantation

Detailed Description
-----------------
Since the start of transcatheter aortic valve implnatations/replacements (TAVR/TAVI) implantations in Sweden in 2008 all procedures have been added to a national database, which now contains 4500+ procedures. At the same time, all admissions to the hospital is also recorded with diagnosis in a separate database. We intend to make a nation-wide complete follow up of all TAVR/TAVI patients in swede that has received the diagnosis of infective endocarditis after the implantation. In addition data will also be collected from the national endocarditis database for detailed information of the cases.

Official Title
-----------------
INfecTive ENdocarditis After Transcatheter Aortic Valve Replacement (TAVR) a National SwEdish Study (INTENSE)

Conditions
-----------------
Infective Endocarditis of Aortic Valve

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients that has under TAVR/TAVI in Sweden between 2008 and 2018 Exclusion Criteria: Patients unable to follow up due to emigration or missing social security number
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patient with infective endocarditis<br>All patients diagnosed with infective endocarditis after TAVR | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Infective Endocarditis | Patients that have suffered an infective endocarditis will be described, where survival is one important variable | 5 year |
Pancreatic Stent for Distal Pancreatectomy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare outcomes of patients undergoing distal pancreatectomy with or without pancreatic stent

Official Title
-----------------
A Prospective Randomized Controlled Study Comparing Outcomes of Distal Pancreatectomy With or Without Pancreatic Stent

Conditions
-----------------
Distal Pancreatectomy

Intervention / Treatment
-----------------
* Device: Pancreatic stent: PSOF COOK®


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing distal pancreatectomy Signed the informed consents Exclusion Criteria: Recurrence patients pre-operative anti-cancer treatment patients with contraindication(hepatic/ respiratory/ renal dysfunction, etc ) AJCC stage IV pre operative oddi'ssphincter incision operation non radical pancreatic stent not at place

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Distal Pancreatectomy without pancreatic stent<br> | |
| Experimental: Distal Pancreatectomy with pancreatic stent<br>pancreatic stent will be placed in the main pancreatic duct during the operation | Device: Pancreatic stent: PSOF COOK®<br>* After removing the distal pancreas, PSOF COOK will be place in the main pancreatic duct<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| all-cause mortality / complications | mortality, pancreatic fistula, Biliary fistula，bleeding， etc | Hospitalization 30days（duration of hospital stay) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| all-cause mortality / complications | mortality, pancreatic fistula, Biliary fistula，bleeding， etc | 30 days after operation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Distal Pancreatectomy, Pancreatic stent, Post-operative pancreatic fistula
A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Participants With Cystic Fibrosis (CF)

Study Overview
=================
Brief Summary
-----------------
This study will evaluate the effects of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) on cough and physical activity using wearable technology in CF participants.

Official Title
-----------------
A Phase 3b Open-label Study Evaluating the Effects of Elexacaftor/Tezacaftor/Ivacaftor on Cough and Physical Activity in Cystic Fibrosis Subjects 12 Years of Age and Older Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

Conditions
-----------------
Cystic Fibrosis

Intervention / Treatment
-----------------
* Drug: ELX/TEZ/IVA
* Drug: IVA


Participation Criteria
=================
Eligibility Criteria
-----------------
Key Inclusion Criteria: Forced expiratory volume in 1 second (FEV1) value ≥30% and ≤90% predicted Heterozygous for CF transmembrane conductance regulator gene (CFTR) F508del mutation and a minimal function mutation (F/MF genotypes) Key Exclusion Criteria: Clinically significant liver cirrhosis Solid organ or hematological transplantation Non-ambulatory status Lung infection with organisms associated with a more rapid decline in pulmonary status Other protocol defined Inclusion/Exclusion criteria may apply.

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: ELX/TEZ/IVA<br>Participants received ELX 200 milligram (mg) once daily (qd)/TEZ 100 mg qd/IVA 150 mg every 12 hours (q12h) in the treatment period approximately 13 weeks. | Drug: ELX/TEZ/IVA<br>* Fixed dose combination (FDC) tablet for oral administration.<br>* Other names: elexacaftor/tezacaftor/ivacaftor;Drug: IVA<br>* Tablet for oral administration.<br>* Other names: ivacaftor;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percent Reduction From Baseline in Cough Frequency (Cough Events Per Day) to the Average of Week 8 Through Week 12 | Percent reduction in cough frequency was analyzed with a mixed effects model for repeated measures (MMRM), with change from baseline at each post-baseline visit on the natural log scale as the dependent variable. The percent reduction was estimated as 100% × (1-exponential form of LS mean change estimate from the MMRM). | Baseline, Week 8 through Week 12 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Absolute Change From Baseline in Total Step Count Per Day to the Average of Week 8 Through Week 12 |  | Baseline, Week 8 through Week 12 |
Study of Safety, Efficacy, and Pharmacokinetics of Topical ACD440 in Healthy Volunteers

Study Overview
=================
Brief Summary
-----------------
Phase 1 b placebo-controlled study in healthy volunteers to study safety, efficacy and pharmacokinetics of Topical ACD440 on normal skin, skin optimized for penetration and skin exposed to ultraviolet radiation

Detailed Description
-----------------
This is an exploratory study, no primary or secondary endpoints are being defined.

Official Title
-----------------
Prospective,Double-blind,Randomized,Placebo-controlled Study of Safety,Efficacy, and Pharmacokinetics of Topical ACD440 in Healthy Volunteers

Conditions
-----------------
Pain

Intervention / Treatment
-----------------
* Drug: ACD440
* Drug: PLAC


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy volunteer Fitzpatrick skin type II or III Women not childbearing potential or highly effective contraception Exclusion Criteria: Pregnancy, lactation Drug abuse Clinically significant illness Positive COVID 19 test at screening or COVID 19 infection in the past

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 64 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: ACD440<br>Subjects are simultaneously exposed to topical administration of ACD440 in a crossover design in separate locations from the placebo exposure. | Drug: ACD440<br>* Double blind, parallel within subject comparison<br>|
| Placebo Comparator: Placebo<br>Subjects are simultaneously exposed to topical administration of placebo in a crossover design in separate locations from the ACD440 exposure. | Drug: PLAC<br>* Double blind, parallel within subject comparison<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Laser-evoked potentials as a tool for assessing the efficacy of antinociceptive drugs | Not defined as primary as per protocol, but system does not seem to allow omittance of primaries | 5 Days |
Fusion Assessment Clinical Trial

Study Overview
=================
Brief Summary
-----------------
This is an observational study to assess clinical outcomes in patients who undergo spinal fusion. Patients who are already scheduled for spinal fusion will enroll in the study. Information about prior therapies will be collected, and then patients will be followed to see how they do after spinal fusion. This study will help researchers better understand the natural course of patients who patients who undergo spinal fusion surgery.

Official Title
-----------------
Fusion Assessment Clinical Trial (FACT)

Conditions
-----------------
Degenerative Disc Disease

Intervention / Treatment
-----------------
* Procedure: Spinal fusion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Lumbar DDD Candidate for spinal fusion Provide written informed consent Exclusion Criteria: Prior lumbar spinal fusion Metabolic bone disease Morbid obesity Systemic infection or active malignancy Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Observation<br>Spinal fusion | Procedure: Spinal fusion<br>* Spinal fusion<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Association Between Testosterone Levels and COPD Severity

Study Overview
=================
Brief Summary
-----------------
The Aims of the study are estimate the association between the severity of COPD and free testosterone level and the prevalence of hypogonadism in adult men with stable COPD

Official Title
-----------------
Association Between Testosterone Levels and COPD Severity Measured by BODE Index in Men

Conditions
-----------------
Chronic Obstructive Pulmonary Disease, Hypogonadism

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults Men ≥ 45 years COPD defined according to clinical diagnosis and spirometry American thoracic society ( ATS) criteria Stable COPD without recent acute exacerbation (less than 2 weeks) Exclusion Criteria: Refusal to participate or informed consent process Those who are under treatment with testosterone replacement or anti-androgens Comorbidities: Cirrhosis, Alcoholism, cryptorchidism, panhypopituitarism, Pituitary adenoma. Orchiectomy Systemic glucocorticoids (equivalent dose ≥ 4 mg of prednisone in the last 3 weeks). Relative and absolute contraindications for spirometry.

Ages Eligible for Study
-----------------
Minimum Age: 45 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Free testosterone Level |  | One day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of Hypogonadism |  | One day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hypogonadism, Chronic Obstructive Pulmonary Disease, Severity of Illness Index, Testosterone
Nutrition and Cognitive Function in Preadolescents

Study Overview
=================
Brief Summary
-----------------
This study is designed to evaluate cognitive function in preadolescents who have different body mass indexes.

Detailed Description
-----------------
The investigators plan to document differences between normal weight and obese preadolescents on psychological and neurocognitive measures of executive function controlling for factors known to influence brain function and behavior not considered in previous studies.

Official Title
-----------------
Nutrition and Cognitive Function in Preadolescents

Conditions
-----------------
Healthy Children

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Normal weight (BMI: <85th percentile) or obese (BMI: >95th percentile) Right hand dominance Report eating breakfast at least 4 days/week Able to hear at least 20 dB stimulus Visual acuity must be at least 20/40 Arithmetic Computation Task Biological mother available to attend the enrollment study visit Exclusion Criteria: Full Scale IQ <80 Children taking medications or having chronic illnesses/disorders that may independently affect study outcome measures (as determined by the PI)

Ages Eligible for Study
-----------------
Minimum Age: 9 Years
Maximum Age: 11 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Normal weight<br>BMI <85th percentile | |
| Obese<br>BMI > 95th percentile | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Psychological assessments | Standardized assessments | 9-10 years | 
| Neurocognitive measures | Brain Lab Recordings | 9-10 years |
Study on Clinical Features, Treatment Mode and Survival of Bone and Soft Tissue Tumors

Study Overview
=================
Brief Summary
-----------------
It is planned to prospectively collect, collate and report real-world clinical data of BSTS patients treated in our hospital in the next ten years to evaluate the changes in clinical characteristics, treatment patterns and survival information of these patients, in order to provide reference for clinical treatment and research of this type of tumor.

Detailed Description
-----------------
It is planned to prospectively collect, collate and report real-world clinical data of BSTS patients treated in our hospital in the next ten years to evaluate the changes in clinical characteristics, treatment patterns and survival information of these patients, in order to provide reference for clinical treatment and research of this type of tumor. This study is a single-center, prospective, real-world observational study that plans to enroll all eligible patients. Basic information, treatment methods, and prognostic information of these patients were collected.

Official Title
-----------------
Single-center Real World Prospective Observational Study of Clinical Features, Treatment Patterns, and Survival of Bone and Soft Tissue Tumors

Conditions
-----------------
Bone and Soft Tissue Tumors, Clinical Features

Intervention / Treatment
-----------------
* Other: NO Intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All ages, male and female. The pathological diagnosis of BSTS in our hospital was a subtype. Has received at least one hospitalization in this hospital. The target lesions could be evaluated according to the efficacy evaluation criteria of solid tumor (RECIST; Version 1.1) Measure diameter changes. Exclusion Criteria: No definite pathology.

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: NO Intervention|NO Intervention|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival | Pathologically confirmed events leading to death | Up to approximately 120months | 
| 6/5000 Progression-free survival | The time from the first use of the treatment to the observation of disease progression | Up to approximately 48months |